A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer

You must be a registrant of the European Society of Gynaecological Oncology (ESGO) State of the Art Conference 2020 Virtual Meeting in order to access this event. Registration information can be found here: 

Join us for this dynamic, CME symposium where ovarian cancer experts will review the evolving role of PARP inhibitors in the treatment of ovarian cancer, including patient case discussions and discussion of new data.

Thank you for your interest in attending the Clinical Care Options (CCO) Webinar, “A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer.”

Please note that this live Webinar will feature the expert faculty, along with interactivity, evidence-based content, and panel discussions. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


Genetic drivers of ovarian cancer development - Dr. Leary

Comparison of pharmacologic properties of approved PARP inhibitors - Dr. Marmé

PARP inhibitor-related adverse event identification and management – Dr. Ledermann

Live attendee Q&A


Date / Time
Event Details


Program Director
Jonathan Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology,
CRUK and UCL Cancer Trials Centre,
UCL Cancer Institute, London UK

Alexandra Leary, MD, PhD

Medical Oncologist and Team Leader, Gynecology Translational Research Lab,
Department of Medicine,
Gustave Roussy Cancer Center,
Paris, France

Frederik Marmé, MD PhD

Assistant Professor of Gynecology,
Medical Faculty of Heidelberg,
University of Heidelberg, Germany

Goal Statement
The goal of this activity is to improve global learners’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize the use of PARP inhibitors for the treatment of patients with ovarian cancer.

Target Audience
This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess recent clinical data on the safety and efficacy of PARP inhibitors for the frontline treatment of ovarian cancer
  • Recognize PARP inhibitor–related toxicities and define supportive management strategies to minimize these adverse events
  • Discuss ongoing clinical research evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy, and immunotherapy as frontline therapy for ovarian cancer to aid referral for clinical trial participation


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.